RTP Mobile Logo
Year in Review — Proceedings from a Multitumor CME Symposium Focused on Key Clinical Presentations and Papers in Oncology
Released February 2015

Proceedings from a daylong symposium featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, multiple myeloma, non-small cell lung cancer and Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia. Including perspectives from Drs Mark D Pegram, Denise A Yardley, Charles S Fuchs, J Randolph Hecht, Myron S Czuczman, Ian W Flinn, Christopher Flowers, Craig Moskowitz, David R Spigel, Heather Wakelee, David F McDermott, Daniel P Petrylak, Omid Hamid, Irene M Ghobrial and Joseph Mikhael. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

    OVERVIEW OF ACTIVITY
    Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing clinical questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a daylong symposium combine the perspectives of 15 renowned investigators with a review of key recent presentations and publications across breast cancer, gastrointestinal cancers, genitourinary cancers, multiple myeloma, non-small cell lung cancer and Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia, to assist medical oncologists and hematologists in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES
    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers.
    • Compare and contrast the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers, and refer appropriate patients for study participation.
    • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDrs Spigel and Yardley have no real or apparant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Mark D Pegram, MD
    Susy Yuan-Huey Hung Professor of Medicine
    Director of the Breast Oncology Program
    Co-Director, Translational Oncology Program
    Associate Director for Clinical Research
    Stanford Cancer Institute
    Stanford University School of Medicine
    Stanford, California

    Consulting Agreements: Celgene Corporation, Cepheid, Genentech BioOncology, Shionogi Inc.

    Denise A Yardley, MD
    Senior Investigator, Breast Cancer Research
    Sarah Cannon Research Institute
    Tennessee Oncology, PLLC
    Nashville, Tennessee

    No financial interests or affiliations to disclose.

    Omid Hamid, MD
    Chief of Research/Immuno-Oncology
    Director of Melanoma Program
    The Angeles Clinic and Research Institute
    Los Angeles, California

    Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Pfizer Inc; Contracted Research: Abbott Laboratories, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology.

    David F McDermott, MD
    Associate Professor of Medicine
    Harvard Medical School
    Director, Biologic Therapy and Cutaneous Oncology Programs
    Beth Israel Deaconess Medical Center
    Leader, Kidney Cancer Program
    Dana-Farber Harvard Cancer Center
    Boston, Massachusetts

    Advisory Committee: Pfizer Inc; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Roche Laboratories Inc; Contracted Research: Novartis Pharmaceuticals Corporation.

    Charles S Fuchs, MD, MPH
    Director, Center for Gastrointestinal Cancer
    Dana-Farber/Harvard Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Acceleron Pharma, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Metamark Genetics Inc, Pfizer Inc, POZEN Inc, Sanofi, Takeda Oncology; Consulting Agreements: Acceleron Pharma, Celgene Corporation, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Metamark Genetics Inc, Pfizer Inc, POZEN Inc, Roche Laboratories Inc, Sanofi, Takeda Oncology.

    J Randolph Hecht, MD
    Professor of Clinical Medicine
    Carol and Saul Rosenzweig Chair in Cancer Therapies Development
    Director, UCLA GI Oncology Program
    Santa Monica, California

    Advisory Committee: Amgen Inc, Genentech BioOncology, Sanofi.

    Irene M Ghobrial, MD
    Assistant Professor in Medicine
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

    Joseph Mikhael, MD, MEd
    Associate Dean, Mayo School of Graduate Medical Education
    Deputy Director - Education, Mayo Clinic Cancer Center
    Associate Professor, Mayo College of Medicine
    Mayo Clinic in Arizona
    Scottsdale, Arizona

    Contracted Research: Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi.

    David R Spigel, MD
    Program Director, Lung Cancer Research
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No financial interests or affiliations to disclose.

    Heather Wakelee, MD
    Associate Professor of Medicine
    Division of Oncology
    Stanford University School of Medicine
    Stanford Cancer Institute
    Stanford, California

    Consulting Agreements: Peregrine Pharmaceuticals Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Xcovery.

    Daniel P Petrylak, MD
    Professor of Medicine
    Director, Prostate and GU Medical Oncology
    Co-Director, Signal Transduction Program
    Yale Cancer Center
    New Haven, Connecticut

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Ferring, Johnson & Johnson Pharmaceuticals, Medivation Inc, Pfizer Inc, Sanofi, Takeda Oncology; Contracted Research: Celgene Corporation, Sanofi, Takeda Oncology; Grant Support: Dendreon Corporation, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc.

    Myron S Czuczman, MD
    Chief, Lymphoma/Myeloma Service
    Head, Lymphoma Translational Research Laboratory
    Roswell Park Cancer Institute
    Professor of Medicine
    School of Medicine and Biomedical Sciences
    State University of New York at Buffalo
    Buffalo, New York

    Advisory Committee: Algeta ASA, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Gilead Sciences Inc, Mundipharma International Limited, Teva Oncology.

    Ian W Flinn, MD, PhD
    Director of Blood Cancer Research
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology.

    Christopher Flowers, MD, MS
    Associate Professor of Hematology and Medical Oncology
    Emory School of Medicine Winship Cancer Institute
    Atlanta, Georgia

    Advisory Committee: Biogen Idec, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Algeta ASA, Celgene Corporation, OptumRx Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Spectrum Pharmaceuticals Inc, Takeda Oncology.

    Craig Moskowitz, MD
    Clinical Director, Division of Hematologic Oncology
    Attending Physician, Lymphoma and Adult BMT Services
    Member, Memorial Sloan Kettering Cancer Center
    Professor of Medicine, Weill Medical College of Cornell University
    New York, New York

    Advisory Committee: Genentech BioOncology, Seattle Genetics; Contracted Research: Genentech BioOncology, GlaxoSmithKline, Merck, Seattle Genetics.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Sanofi, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:

    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2015
    Expiration date: February 2016

Acknowledge and close

View video: